US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent [View all]

Source: Reuters

US Supreme Court rebuffs Novartis bid to revive MS drug Gilenya patent

Blake Brittain
Mon, April 17, 2023 at 9:45 AM EDT·2 min read

WASHINGTON (Reuters) -The U.S. Supreme Court on Monday declined to hear Novartis Pharmaceuticals Corp's bid to revive a key patent on its blockbuster multiple sclerosis drug Gilenya that was invalidated amid a legal dispute with China's HEC Pharm Co Ltd.

The justices turned away an appeal by Novartis of a lower court's decision to cancel the patent, a ruling that paved the way for some generic versions of Gilenya.

Novartis sold $1.1 billion worth of Gilenya in the U.S. last year, a 19% drop from 2021 that was caused in part by generic competition, according to a company report.

The U.S. Food and Drug Administration in 2010 approved Gilenya to treat relapsing forms of multiple sclerosis, a chronic disease that affects the central nervous system.

Novartis sued HEC and more than a dozen other generic drugmakers for patent infringement ...

-snip-

Read more: https://news.yahoo.com/us-supreme-court-rebuffs-novartis-134525497.html